COMP <GO>
KLRA vs NBTX // REVENUE GROWTH (YOY)
Kailera Therapeutics Inc. (NASDAQ) VS. Nanobiotix S.A. (NASDAQ) • 15-METRIC TALLY: KLRA 1
— NBTX 1
■ METRIC PARITY
LAST: $13.41 (-0.07%) • MKT CAP: $1.74B
revenue-growth
—
LAST: $33.80 (-0.53%) • MKT CAP: $1.72B
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KLRA VS. NBTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KLRA | NBTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 55.4 | -3.03 | NBTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.74B | $1.72B | $21.2M | KLRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KLRA REV | NBTX REV | KLRA GROSS % | NBTX GROSS % | KLRA FCF | NBTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | — | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KLRA // BETA —
NBTX // BETA —